Protein expression of targets of the FMRP regulon is altered in brains of subjects with schizophrenia and mood disorders
| Autor: | Paul Thuras, S. Hossein Fatemi, Timothy D. Folsom |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Receptor Metabotropic Glutamate 5 Protein tyrosine phosphatase Regulon Article Cohort Studies Fragile X Mental Retardation Protein mental disorders Presenilin-1 medicine Humans RNA Messenger Bipolar disorder Biological Psychiatry Aged Aged 80 and over Analysis of Variance Mood Disorders Metabotropic glutamate receptor 5 Brain Middle Aged medicine.disease FMR1 Molecular Weight Fragile X syndrome Psychiatry and Mental health Mood disorders Schizophrenia Phosphopyruvate Hydratase Autism Female Protein Tyrosine Phosphatases Psychology Neuroscience Signal Transduction |
| Zdroj: | Schizophrenia Research. 165:201-211 |
| ISSN: | 0920-9964 |
| DOI: | 10.1016/j.schres.2015.04.012 |
| Popis: | Fragile X mental retardation protein (FMRP) is an RNA binding protein with 842 target mRNAs in mammalian brain. Silencing of the fragile X mental retardation 1 (FMR1) gene leads to loss of expression of FMRP and upregulated metabotropic glutamate receptor 5 (mGluR5) signaling resulting in the multiple physical and cognitive deficits associated with fragile X syndrome (FXS). Reduced FMRP expression has been identified in subjects with autism, schizophrenia, bipolar disorder, and major depression who do not carry the mutation for FMR1. Our laboratory has recently demonstrated altered expression of four downstream targets of FMRP-mGluR5 signaling in brains of subjects with autism: homer 1, amyloid beta A4 precursor protein (APP), ras-related C3 botulinum toxin substrate 1 (RAC1), and striatal-enriched protein tyrosine phosphatase (STEP). In the current study we investigated the expression of the same four proteins in lateral cerebella of subjects with schizophrenia, bipolar disorder, and major depression and in frontal cortex of subjects with schizophrenia and bipolar disorder. In frontal cortex we observed: 1) reduced expression of 120 kDa form of APP in subjects with schizophrenia and bipolar disorder; 2) reduced expression of 61 kDa and 33k Da forms of STEP in subjects with schizophrenia; 3) reduced expression of 88 kDa form of APP in subjects with bipolar disorder; and 3) trends for reduced expression of 88 kDa form of APP and homer 1 in subjects with schizophrenia and bipolar disorder, respectively. In lateral cerebella there was no group difference, however we observed increased expression of RAC1 in subjects with bipolar disorder, and trends for increased RAC1 in subjects with schizophrenia and major depression. Our results provide further evidence that proteins involved in the FMRP-mGluR5 signaling pathway are altered in schizophrenia and mood disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect